| Name | Stavudine |
| Description | Stavudine (BMY-27857), a nucleoside reverse transcriptase inhibitor analog of thymidine, has activity against HIV. |
| In vitro | In lean mice, Stavudine (500 mg/kg/day) reduces mitochondrial DNA in the liver and muscle, inducing ketoacidosis during fasting periods. In obese mice, Stavudine (500 mg/kg/day) depletes mtDNA in White Adipose Tissue (WAT). |
| In vivo | Stavudine reduces lipid content and influences the expression of lipid metabolism markers, such as C/EBPα, peroxisome proliferator-activated receptor γ, adipocyte lipid-binding protein 2, fatty acid synthase, and acetyl-CoA carboxylase. In 3T3-F442A cells, Stavudine induces apoptosis and reduces both lipid content and viability in 3T3-L1 adipocytes. Furthermore, in peripheral blood mononuclear cells (PBMC), Stavudine inhibits the production of p24 antigen by HIV-1, with an effective dose range of 0.04 μM to 0.2 μM (ED50 = 0.04 μM-0.2 μM). |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 50 mg/mL (223.01 mM)
H2O : 22.4 mg/mL (100 mM)
|
| Keywords | BMY27857 | nucleoside | inflammasome | Autophagy | NSC-163661 | mtDNA | Apoptosis | inhibit | HIV | NOD-like Receptor (NLR) | antiretroviral | analogue | Stavudine | Inhibitor | Reverse Transcriptase | Human immunodeficiency virus | Amyloid-β | NSC163661 | BMY 27857 | Nucleoside Antimetabolite/Analog |
| Inhibitors Related | Emtricitabine | Sodium 4-phenylbutyrate | Hydroxychloroquine | Guanidine hydrochloride | Lamivudine | Tributyrin | Paeonol | Naringin |
| Related Compound Libraries | Bioactive Compound Library | EMA Approved Drug Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Anti-Viral Compound Library | Inhibitor Library | Anti-Cancer Approved Drug Library | FDA-Approved Drug Library | Anti-Aging Compound Library | Anti-Cancer Drug Library |
United States
